Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Med Food ; 25(5): 503-512, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-35483086

RESUMEN

The abnormal change of vascular smooth muscle cell (VSMC) behavior is an important cellular event leading to neointimal hyperplasia in atherosclerosis and restenosis. Plantamajoside (PMS), a phenylethanoid glycoside compound of the Plantago asiatica, has been reported to have anti-inflammatory, antioxidative, and anticancer activities. In this study, the protective effects of PMS against intimal hyperplasia and the mechanisms underlying the regulation of VSMC behavior were investigated. MTT and BrdU assays were performed to evaluate the cytotoxicity and cell proliferative activity of PMS, respectively. Rat aortic VSMC migrations after treatment with the determined concentration of PMS (50 and 150 µM) were evaluated using wound healing and Boyden chamber assays. The inhibitory effects of PMS on intimal hyperplasia were evaluated in balloon-injured (BI) rat carotid artery. PMS suppressed the proliferation in platelet-derived growth factor-BB-induced VSMC, as confirmed from the decrease in cyclin-dependent kinase (CDK)-2, CDK-4, cyclin D1, and proliferating cell nuclear antigen levels. PMS also inhibited VSMC migration, consistent with the downregulated expression and zymolytic activities of matrix metalloproteinase (MMP)2, MMP9, and MMP13. PMS specifically regulated MMP expression through p38 mitogen-activated protein kinase and focal adhesion kinase pathways. Tissue inhibitor of metalloproteinase (TIMP)1 and TIMP2 levels were upregulated via Smad1. TIMPs inhibited the conversion of pro-MMPs to active MMPs. PMS significantly inhibited neointimal formation in BI rat carotid arteries. In conclusion, PMS inhibits VSMC proliferation and migration by upregulating TIMP1 and TIMP2 expression. Therefore, PMS could be a potential therapeutic agent for vascular atherosclerosis and restenosis treatment.


Asunto(s)
Aterosclerosis , Neointima , Animales , Aterosclerosis/metabolismo , Catecoles , Movimiento Celular , Proliferación Celular , Células Cultivadas , Glucósidos , Hiperplasia/tratamiento farmacológico , Hiperplasia/metabolismo , Hiperplasia/patología , Músculo Liso Vascular , Miocitos del Músculo Liso , Neointima/tratamiento farmacológico , Neointima/metabolismo , Neointima/patología , Ratas , Ratas Sprague-Dawley , Inhibidores Tisulares de Metaloproteinasas/metabolismo , Inhibidores Tisulares de Metaloproteinasas/farmacología , Inhibidores Tisulares de Metaloproteinasas/uso terapéutico , Regulación hacia Arriba
2.
Minerva Endocrinol ; 40(2): 85-103, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25651758

RESUMEN

The safety and effectiveness of islet transplantation has been proven through world-wide trials. However, acute and chronic islet loss has hindered the ultimate objective of becoming a widely used treatment option for type 1 diabetes. A large islet loss is attributed, in part, to the liver being a less-than-optimal site for transplantation. Over half of the transplanted islets are destroyed shortly after transplantation due to direct exposure to blood and non-specific inflammation. Successfully engrafted islets are continuously exposed to the liver micro-environment, a unique immune system, low oxygen tension, toxins and high glucose, which is toxic to islets, leading to premature islet dysfunction/death. Investigations have continued to search for alternate sites to transplant islets that provide a better environment for prolonged function and survival. This article gathers courses and conditions that lead to islet loss, from organ procurement through islet transplantation, with special emphasis on hypoxia, oxidative stress, and antigen non-specific inflammation, and reviews strategies using pharmacological agents that have shown effectiveness in protecting islets, including a new treatment approach utilizing siRNA. Pharmacological agents that support islet survival and promote ß-cell proliferation are also included. Treatment of donor pancreata and/or islets with these agents should increase the effectiveness of islets transplanted into extrahepatic sites. Furthermore, the development of methods designed to release these agents over an extended period, will further increase their efficacy. This requires the combined efforts of both islet transplant biologists and bioengineers.


Asunto(s)
Trasplante de Islotes Pancreáticos/métodos , Hígado/cirugía , Trasplante Heterotópico/métodos , Inductores de la Angiogénesis/farmacología , Inductores de la Angiogénesis/uso terapéutico , Animales , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Hipoxia de la Célula/efectos de los fármacos , Microambiente Celular , Evaluación Preclínica de Medicamentos , Técnicas de Silenciamiento del Gen , Péptido 1 Similar al Glucagón/agonistas , Péptido 1 Similar al Glucagón/farmacología , Péptido 1 Similar al Glucagón/uso terapéutico , Glucosa/metabolismo , Supervivencia de Injerto/efectos de los fármacos , Humanos , Inmunosupresores/farmacología , Inmunosupresores/uso terapéutico , Péptidos y Proteínas de Señalización Intercelular/farmacología , Péptidos y Proteínas de Señalización Intercelular/uso terapéutico , Islotes Pancreáticos/efectos de los fármacos , Hígado/citología , Hígado/inmunología , Hígado/metabolismo , Ratones , Especificidad de Órganos , Estrés Oxidativo/efectos de los fármacos , ARN Interferente Pequeño/farmacología , ARN Interferente Pequeño/uso terapéutico , Inhibidores Tisulares de Metaloproteinasas/farmacología , Inhibidores Tisulares de Metaloproteinasas/uso terapéutico , Obtención de Tejidos y Órganos/métodos
4.
Medicina (Kaunas) ; 40(12): 1143-50, 2004.
Artículo en Lituano | MEDLINE | ID: mdl-15630339

RESUMEN

The cancer cells secrete proteolytic enzymes, which are important in the tumor spreading. The cells must cross basement membrane and extracellular matrix barriers in order to spread. The matrix metalloproteinases are a family of endopeptidases, which enzymatic activity depends on the presence of zinc ion in the catalytic domain. Matrix metalloproteinases hydrolyze extracellular matrix components such as collagen, laminin, fibronectin, proteoglycans and contribute to the spreading of tumor cells by eliminating the surrounding extracellular matrix and basement membrane barriers. This review describes matrix metalloproteinases family classification and structure, their role under physiological conditions and induced proteolysis during pathological processes. There is a balance between proteolytic extracellular matrix degradation and proteolysis inhibition, but under pathological state (e. g. tumor development) the proteolysis becomes uncontrolled. We review tissue inhibitors of matrix metalloproteinases and synthetic matrix metalloproteinase inhibitors, their perspective in cancer treatment; as well as different matrix metalloproteinases expression in patients with tumors and its prognostic significance during cancer progression.


Asunto(s)
Antineoplásicos/uso terapéutico , Metaloproteinasas de la Matriz/metabolismo , Neoplasias/tratamiento farmacológico , Neoplasias/enzimología , Inhibidores Tisulares de Metaloproteinasas/uso terapéutico , Antineoplásicos/administración & dosificación , Apoptosis , Compuestos de Bifenilo , Ensayos Clínicos como Asunto , Difosfonatos/uso terapéutico , Progresión de la Enfermedad , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/uso terapéutico , Regulación Enzimológica de la Expresión Génica , Humanos , Ácidos Hidroxámicos/administración & dosificación , Ácidos Hidroxámicos/uso terapéutico , Imidazoles/administración & dosificación , Imidazoles/uso terapéutico , Inhibidores de la Metaloproteinasa de la Matriz , Metaloproteinasas de la Matriz/clasificación , Metaloproteinasas de la Matriz/fisiología , Neoplasias/metabolismo , Compuestos Orgánicos/administración & dosificación , Compuestos Orgánicos/uso terapéutico , Fenilalanina/análogos & derivados , Fenilalanina/uso terapéutico , Fenilbutiratos , Pronóstico , Inhibidores de Proteasas/administración & dosificación , Inhibidores de Proteasas/uso terapéutico , Tiofenos/uso terapéutico , Factores de Tiempo , Inhibidores Tisulares de Metaloproteinasas/administración & dosificación
6.
J Thorac Cardiovasc Surg ; 125(3): 602-10, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12658202

RESUMEN

BACKGROUND: Global and regional shape changes that occur within the left ventricular wall after myocardial infarction have been termed infarct expansion. A potential mechanism for this postinfarction remodeling is activation of the matrix metalloproteinases. Accordingly, the present study examined the effects of matrix metalloproteinase inhibition on left ventricular global geometry after myocardial infarction in pigs. METHODS: Myocardial infarction was created in pigs by means of occlusion of the first and second obtuse marginal branches of the circumflex coronary artery, resulting in a uniform left ventricular free wall infarct size of 21% +/- 2%. At 5 days after infarction, the pigs were randomized to undergo broad-spectrum matrix metalloproteinase inhibition (n = 9; PD166793, 20 mg. kg(-1). d(-1) by mouth) or myocardial infarction alone (n = 8). Ten pigs served as noninfarction control animals. Left ventricular end-diastolic area, determined by means of echocardiography, was measured 8 weeks after infarction. RESULTS: Left ventricular end-diastolic area increased in both the myocardial infarction plus broad-spectrum matrix metalloproteinase inhibition and myocardial infarction only groups compared to reference control animals (3.7 +/- 0.2 cm(2)), but was reduced with broad-spectrum matrix metalloproteinase inhibition compared to myocardial infarction alone (4.5 +/- 0.2 vs 4.9 +/- 0.2 cm(2), respectively; P <.05). Regional radial stress within the infarct region increased in both infarction groups when compared to values obtained from reference control animals (599 +/- 152 g/cm(2)), but was attenuated in the myocardial infarction plus broad-spectrum matrix metalloproteinase inhibition group compared to the myocardial infarction alone group (663 +/- 108 vs 1242 +/- 251 g/cm(2), respectively; P <.05). Similarly, regional myocardial stiffness increased in both the myocardial infarction plus broad-spectrum matrix metalloproteinase inhibition and the myocardial infarction only groups compared with that observed in reference control animals (14 +/- 1 rkm, P <.05) but was lower with broad-spectrum matrix metalloproteinase inhibition than with myocardial infarction alone (42 +/- 6 vs 68 +/- 10 rkm, respectively; P <.05). CONCLUSIONS: Matrix metalloproteinase inhibition reduced postinfarction left ventricular dilation, reduced regional myocardial wall stress, and modified myocardial material properties. These unique findings suggest that increased myocardial matrix metalloproteinase activation after infarction contributes directly to the left ventricular remodeling process.


Asunto(s)
Modelos Animales de Enfermedad , Ácidos Hidroxámicos/uso terapéutico , Inhibidores de la Metaloproteinasa de la Matriz , Metaloproteinasas de la Matriz/fisiología , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/enzimología , Oligopéptidos/uso terapéutico , Inhibidores Tisulares de Metaloproteinasas/uso terapéutico , Disfunción Ventricular Izquierda/etiología , Remodelación Ventricular/efectos de los fármacos , Análisis de Varianza , Animales , Progresión de la Enfermedad , Evaluación Preclínica de Medicamentos , Ecocardiografía Transesofágica , Hemodinámica/efectos de los fármacos , Ácidos Hidroxámicos/farmacología , Infarto del Miocardio/complicaciones , Infarto del Miocardio/diagnóstico , Oligopéptidos/farmacología , Distribución Aleatoria , Volumen Sistólico/efectos de los fármacos , Porcinos , Factores de Tiempo , Inhibidores Tisulares de Metaloproteinasas/farmacología , Disfunción Ventricular Izquierda/prevención & control , Presión Ventricular/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA